StreetInsider.com News Articles

Form 8-K AIM ImmunoTech Inc. For: Jul 15

Thu, 16 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260716/26779683.html

Form 8-K AIM ImmunoTech Inc. For: Jul 15

Thu, 16 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260716/26779683.html

Form S-8 AIM ImmunoTech Inc.

Thu, 09 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260709/26753248.html

Form S-8 AIM ImmunoTech Inc.

Thu, 09 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260709/26753248.html

AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program

Tue, 07 Jul 2026 09:03:00 -0400

Access it here

OCALA, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of its latest CEO Corner segment, featuring Chief Executive Officer Thomas Equels discussing the Company's continued momentum in pancreatic cancer and the significant clinical, strategic and operational milestones positioning Ampligen® for its next stage of development.

In the segment, Mr. Equels highlights the urgent unmet need facing patients with pancreatic cancer, reviews recent progress across the Company's DURIPANC Phase 2 clinical program evaluating Ampligen®

AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program

Tue, 07 Jul 2026 09:03:00 -0400

Access it here

AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program

Tue, 07 Jul 2026 09:03:00 -0400

Access it here

AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program

Tue, 07 Jul 2026 09:03:00 -0400

Access it here

Form DEF 14A AIM ImmunoTech Inc. For: Jun 25

Thu, 25 Jun 2026 08:55:00 -0400

si-local-file:///var/storage/secattach/20260625/26688972.html

Form DEF 14A AIM ImmunoTech Inc. For: Jun 25

Thu, 25 Jun 2026 08:55:00 -0400

si-local-file:///var/storage/secattach/20260625/26688972.html

Form 424B3 AIM ImmunoTech Inc.

Wed, 24 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260624/26685974.html

Form 424B3 AIM ImmunoTech Inc.

Wed, 24 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260624/26685974.html

AIM ImmunoTech completes DURIPANC enrollment, eyes 2027 data

Wed, 24 Jun 2026 08:30:00 -0400

AIM ImmunoTech Inc. (NYSE American: AIM) announced it has completed enrollment in its Phase 2 DURIPANC clinical study ahead of schedule and has dosed the final patient in the trial, according to a company press release.

The study is evaluating Ampligen (rintatolimod), a TLR3 agonist immunotherapy, in combination with AstraZeneca's PD-L1 inhibitor Imfinzi (durvalumab) for the treatment of metastatic pancreatic cancer. The trial is being conducted in collaboration with AstraZeneca and Erasmus Medical Center.

The company said primary endpoint analysis is anticipated to begin in December 2026, with topline results expected in the first quarter of 2027. Progression-free survival, overall survival, and

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

Wed, 24 Jun 2026 08:29:00 -0400

OCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted the significant progress achieved across its pancreatic cancer development program and outlined a series of anticipated milestones that position the Company for what management believes could be a pivotal period in its evolution as a clinical-stage oncology company.

At the center of AIM's strategy is Ampligen® (rintatolimod), the Company's proprietary TLR3 agonist immunotherapy, which is being evaluated in the ongoing Phase 2 DURIPANC study in combination with AstraZeneca's PD-L1 inhibitor Imfinzi® (durvalumab) for the

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

Wed, 24 Jun 2026 08:29:00 -0400

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

Wed, 24 Jun 2026 08:29:00 -0400

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

Wed, 24 Jun 2026 08:29:00 -0400

Form EFFECT AIM ImmunoTech Inc.

Wed, 24 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260624/26681769.html

Form EFFECT AIM ImmunoTech Inc.

Wed, 24 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260624/26681769.html

Form 424B3 AIM ImmunoTech Inc.

Thu, 18 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260618/26665942.html

Form 424B3 AIM ImmunoTech Inc.

Thu, 18 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260618/26665942.html

AIM ImmunoTech (AIM) files for 13.08M share offering by selling stockholders

Thu, 18 Jun 2026 08:06:39 -0400

AIM ImmunoTech (NYSE: AIM) has filed for up to 13,077,089 share offering by selling stockholders.

AIM ImmunoTech (AIM) files for 13.08M share offering by selling stockholders

Thu, 18 Jun 2026 08:06:39 -0400

AIM ImmunoTech (NYSE: AIM) has filed for up to 13,077,089 share offering by selling stockholders.

Form S-1 AIM ImmunoTech Inc.

Thu, 18 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260618/26663121.html

Form S-1 AIM ImmunoTech Inc.

Thu, 18 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260618/26663121.html